Microtubule Modulators (Taxanes): Paclitaxel and Docetaxel

Mechanism

Pharmacological Class and Group

Antineoplastic agents that modulate microtubules, belonging to the group of taxanes; specific phase of the cell cycle (G2/M Phase).

Mechanism of Action

Unlike vinca alkaloids that prevent tubulin assembly, taxanes act as promoters and stabilizers of microtubular polymerization.

Mechanism of Microtubule Stabilization and G2/M Arrest

1. Binding to the Beta-Tubulin Domain: The compounds penetrate the cell and bind specifically and reversibly to the N-terminal hydrophobic domain of the β-tubulin subunit of the active polymerized microtubule.

2. Polymer Stabilization: This allosteric binding blocks the physiological exchange of guanosine triphosphate (GTP) nucleotides and promotes an assembly of abnormally stable and rigid microtubules, preventing depolymerization of the cytoskeleton:

Taxane + β-Tubulin Microtubule Stabilization Depolymerization Blockade (G2/M Arrest)

3. Mitotic Spindle Arrest: Without depolymerization, disassembly of the mitotic spindle is not possible during anaphase of mitosis. Sister chromatids are unable to segregate and migrate toward opposite cell poles, resulting in a sustained arrest of mitosis (G2/M phase) that activates the mitotic apoptosis pathway.

Pharmacokinetics

High Resolution Pharmacokinetics

• Protein Distribution and Binding: They exhibit a very high binding to plasma proteins (>95-98%). They are massively distributed in peripheral tissues and deep stroma. They do not cross the blood-brain barrier.
• Metabolism: They undergo extensive phase I hepatic biotransformation mediated by CYP450 isoenzymes. Paclitaxel is metabolized primarily by CYP2C8 to 6α-hydroxypaclitaxel, and secondarily by CYP3A4. Docetaxel is metabolized exclusively by the isoenzyme CYP3A4 to inactive metabolites.
• Elimination: Predominant hepatobiliary clearance, with more than 70-80% of the dose excreted in the feces. Less than 5% of the active dose is cleared renally unchanged.
• Half-life (t_1/2): The half-life of paclitaxel is triphasic, ranging between 15 and 50 hours in a dose-dependent manner due to cellular clearance saturability; that of docetaxel is approximately 11 to 18 hours.

Indicators and dose

Clinical Indications and Frequent Regimens

• Conventional Paclitaxel: Advanced epithelial ovarian cancer (combined with first-line Carboplatin), adjuvant or metastatic breast cancer (dosed weekly at 80 mg/m² to limit neuropathy).
• Albumin-Bound Paclitaxel (Nab-Paclitaxel / Abraxane): Solvent-free nanoparticle formulation. Indicated in metastatic pancreatic adenocarcinoma (combined with gemcitabine) and non-small cell lung cancer, with a lower risk of hypersensitivity and a higher rate of tumor penetration facilitated by the gp60 transporter.
• Docetaxel (TCH Scheme): Breast cancer (Docetaxel + Carboplatin + Trastuzumab in HER2+ disease), metastatic castration-resistant prostate cancer (combined with oral prednisone).

Dosage and Clinical Adjustment

• Conventional IV Paclitaxel: 175 mg/m² as a 3-hour infusion every 21 days, or 80 mg/m² weekly continuous for 12 weeks.
• Docetaxel IV: 75 - 100 mg/m² as a 1-hour infusion every 21 days.
• Adjustments in Liver Failure: Taxanes require strict reduction if transaminases or bilirubin are elevated due to the risk of profound myelosuppression due to delayed phase I hepatic clearance:
  • Bilirubin between 1.5 - 3.0 mg/dL or transaminases > 2.5 times the upper limit of normal (ULN): Reduce the dose of docetaxel by 25-50%. Discontinue paclitaxel or replace with Nab-Paclitaxel if bilirubin exceeds 3 mg/dL.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Known severe hypersensitivity to Cremophor EL (for conventional paclitaxel) or Polysorbate 80 (for docetaxel).
• Marked basal myelosuppression (Neutrophils < 1500/mm³).
• Severe liver failure (total bilirubin > 3 mg/dL).

Relative Contraindications

• Previous peripheral sensory neuropathy of grade 2 or higher.
• Underlying cardiac dysfunction.

Adverse Effects (ADR) and Specific Toxicity

• Hematological: Rapid-course dose-limiting neutropenia, with nadir 8-11 days after the infusion.
• Hypersensitivity: Severe acute infusion reactions due to non-immunological complement activation due to the solvent Cremophor EL (Paclitaxel) or Polysorbate 80 (Docetaxel). It manifests itself with dyspnea, bronchospasm, hypotension and oppressive lumbar pain in the first 10 minutes of infusion. Requires mandatory pretreatment with dexamethasone, diphenhydramine and H2 inhibitor.
• Neurological: Distal symmetrical sensory peripheral neuropathy ("in glove and sock"), with an irreversible cumulative course due to structural damage to the microtubules of the neuronal axon.
• Tissue (Docetaxel): Fluid Retention Syndrome, characterized by progressive massive peripheral edema, pleural effusion or ascites, refractory to diuretics. It is prevented by administering oral dexamethasone (8 mg twice daily) for 3 consecutive days beginning the day before the infusion.